ECOR - electroCore, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Rockaway,
United States
Type: Equity
ECOR price evolution
ECOR
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10.58 | $13.71 | $8.69 | $12.16 |
| Short term investments | ||||
| Net receivables | $0.72 | $0.59 | $0.24 | $0.21 |
| Inventory | $2.77 | $3.31 | $3.72 | $3.93 |
| Total current assets | $14.29 | $17.84 | $11.4 | $15.37 |
| Long term investments | ||||
| Property, plant & equipment | $0.71 | $0.7 | $0.65 | $0.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.81 | $2.27 | $2.82 | $2.93 |
| Total investments | ||||
| Total assets | $16.1 | $20.11 | $14.22 | $18.3 |
| Current liabilities | ||||
| Accounts payable | $2.16 | $3.03 | $2.28 | $2 |
| Deferred revenue | ||||
| Short long term debt | $0.09 | $0.09 | $0.08 | $0.08 |
| Total current liabilities | $8.12 | $8.51 | $6.58 | $5.85 |
| Long term debt | $0.54 | $0.56 | $0.58 | $0.6 |
| Total noncurrent liabilities | $0.54 | $0.56 | $0.58 | $0.6 |
| Total debt | $0.63 | $0.65 | $0.66 | $0.68 |
| Total liabilities | $8.66 | $9.07 | $7.16 | $6.45 |
| Shareholders' equity | ||||
| Retained earnings | -$165.2 | -$161.17 | -$157.14 | -$152.24 |
| Other shareholder equity | -$0.06 | -$0.1 | -$0.08 | -$0.01 |
| Total shareholder equity | $7.44 | $11.04 | $7.06 | $11.85 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10.58 | $17.96 | $34.69 | $4.24 |
| Short term investments | $18.39 | |||
| Net receivables | $0.72 | $0.4 | $0.44 | $0.27 |
| Inventory | $2.77 | $1.98 | $5.3 | $5.74 |
| Total current assets | $14.29 | $21.17 | $37.54 | $25.06 |
| Long term investments | ||||
| Property, plant & equipment | $0.71 | $0.61 | $0.76 | $0.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.81 | $3.58 | $5.29 | $6.45 |
| Total investments | $18.39 | |||
| Total assets | $16.1 | $24.76 | $42.83 | $31.52 |
| Current liabilities | ||||
| Accounts payable | $2.16 | $2.13 | $1.54 | $2.08 |
| Deferred revenue | ||||
| Short long term debt | $0.09 | $0.07 | $0.06 | $1.01 |
| Total current liabilities | $8.12 | $7.04 | $5.49 | $5.89 |
| Long term debt | $0.54 | $0.63 | $0.7 | $1.98 |
| Total noncurrent liabilities | $0.54 | $0.63 | $0.7 | $1.98 |
| Total debt | $0.63 | $0.7 | $0.76 | $2.99 |
| Total liabilities | $8.66 | $7.67 | $6.18 | $7.87 |
| Shareholders' equity | ||||
| Retained earnings | -$165.2 | -$146.37 | -$124.21 | -$106.99 |
| Other shareholder equity | -$0.06 | -$0.07 | $0.01 | -$0.25 |
| Total shareholder equity | $7.44 | $17.09 | $36.65 | $23.01 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.19 | $4.51 | $3.55 | $2.78 |
| Cost of revenue | $1.1 | $0.66 | $0.58 | $0.46 |
| Gross Profit | $4.09 | $3.85 | $2.97 | $2.32 |
| Operating activities | ||||
| Research & development | $1.11 | $1.25 | $1.16 | $1.81 |
| Selling, general & administrative | $6.94 | $6.72 | $6.8 | $6.71 |
| Total operating expenses | $8.05 | $7.97 | $7.95 | $8.52 |
| Operating income | -$3.96 | -$4.13 | -$4.99 | -$6.2 |
| Income from continuing operations | ||||
| EBIT | -$4.01 | -$4.03 | -$4.9 | -$6.08 |
| Income tax expense | $0.03 | -$0.21 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.03 | -$4.03 | -$4.9 | -$5.87 |
| Income (for common shares) | -$4.03 | -$4.03 | -$4.9 | -$5.87 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16.03 | $8.59 | $5.45 | $3.5 |
| Cost of revenue | $2.8 | $1.62 | $1.39 | $1.74 |
| Gross Profit | $13.23 | $6.98 | $4.07 | $1.76 |
| Operating activities | ||||
| Research & development | $5.32 | $5.52 | $2.54 | $4.2 |
| Selling, general & administrative | $27.17 | $24.33 | $21.57 | $21.84 |
| Total operating expenses | $32.49 | $29.85 | $24.11 | $26.51 |
| Operating income | -$19.27 | -$22.87 | -$20.04 | -$24.75 |
| Income from continuing operations | ||||
| EBIT | -$19.02 | -$22.59 | -$18.07 | -$24.68 |
| Income tax expense | -$0.19 | -$0.43 | -$0.85 | -$1.17 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$18.83 | -$22.16 | -$17.22 | -$23.51 |
| Income (for common shares) | -$18.83 | -$22.16 | -$17.22 | -$23.51 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$4.03 | -$4.03 | -$4.9 | -$5.87 |
| Operating activities | ||||
| Depreciation | $0.29 | $0.29 | $0.32 | $0.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.4 | $0.54 | $0.18 | $0.57 |
| Total cash flows from operations | -$3.12 | -$2.37 | -$3.31 | -$5.86 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.07 | -$0.09 | |
| Investments | ||||
| Total cash flows from investing | -$0.04 | -$0.07 | -$0.09 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.14 | |||
| Net borrowings | ||||
| Total cash flows from financing | $7.49 | |||
| Effect of exchange rate | $0.04 | -$0.02 | -$0.06 | $0.06 |
| Change in cash and equivalents | -$3.13 | $5.02 | -$3.47 | -$5.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$18.83 | -$22.16 | -$17.22 | -$23.51 |
| Operating activities | ||||
| Depreciation | $1.02 | $0.6 | $0.44 | $0.77 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.7 | $2.68 | $3.3 | $3.27 |
| Total cash flows from operations | -$14.67 | -$16.64 | -$13.63 | -$20.1 |
| Investing activities | ||||
| Capital expenditures | -$0.21 | |||
| Investments | $18.22 | -$7.96 | ||
| Total cash flows from investing | -$0.21 | $18.22 | -$7.96 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.14 | $25.68 | $17.49 | |
| Net borrowings | $1.46 | |||
| Total cash flows from financing | $7.49 | $25.68 | $18.95 | |
| Effect of exchange rate | $0.01 | -$0.08 | $0.18 | -$0.21 |
| Change in cash and equivalents | -$7.38 | -$16.73 | $30.45 | -$9.32 |
News
|
electroCore, Inc. (NASDAQ:ECOR) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
16 Mar 2024
|
|
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
13 Mar 2024
|
|
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
26 Feb 2024
|
|
These Stocks under $10 Are Poised To Explode
Insider Monkey via Yahoo Finance
21 Dec 2023
|
|
13 Best Biotech Penny Stocks To Buy Now
Insider Monkey via Yahoo Finance
29 Nov 2022
|
|
10 Best Penny Stocks to Buy and Hold According to Reddit
Insider Monkey via Yahoo Finance
1 Aug 2022
|
|
ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine
Benzinga via Yahoo Finance
21 Jan 2022
|
|
52 Biggest Movers From Yesterday
Benzinga
20 Jan 2022
|
|
Omicron Variant Forces Some Drugstores to Shut Temporarily – Report
SmarterAnalyst
17 Jan 2022
|
|
Is electroCore a Good Stock to Add to Your Healthcare Portfolio?
Entrpreneur
14 Jan 2022
|
Fundamentals
| Market cap | $33.49M |
|---|---|
| Enterprise value | $23.54M |
| Shares outstanding | 6.00M |
| Revenue | $16.03M |
|---|---|
| EBITDA | -$18.00M |
| EBIT | -$19.02M |
| Net Income | -$18.83M |
| Revenue Q/Q | 102.77% |
| Revenue Y/Y | 86.57% |
| P/E ratio | -1.78 |
|---|---|
| EV/Sales | 1.47 |
| EV/EBITDA | -1.31 |
| EV/EBIT | -1.24 |
| P/S ratio | 2.09 |
| P/B ratio | 4.46 |
| Book/Share | 1.25 |
| Cash/Share | 1.76 |
| EPS | -$3.14 |
|---|---|
| ROA | -109.61% |
| ROE | -201.47% |
| Debt/Equity | 1.16 |
|---|---|
| Net debt/EBITDA | 0.11 |
| Current ratio | 1.76 |
| Quick ratio | 1.42 |